The approval marks the second Alzheimer's drug facing a split decision in a short span. Despite the Medicines and Healthcare products Regulatory Agency's endorsement of Kisunla, also known as ...

Eli Lilly's donanemab receives UK approval for mild cognitive impairment and mild dementia due to Alzheimer's disease.

Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...

Eli Lilly’s Alzheimer’s disease offering Kinsunla is poised to face a tough road ahead in the U.K. | Lilly's Alzheimer ...

A wife whose husband will not be eligible for new Alzheimer’s drugs has implored health leaders to ensure that others like ...

The UK’s healthcare spending watchdog has rejected Eli Lilly’s (LLY) Alzheimer’s drug as being too expensive despite being ...

Eli Lilly (LLY) announced that the Medicines and Healthcare products Regulatory Agency, or MHRA, has granted marketing authorization for ...

A second groundbreaking drug (donanemab) for Alzheimer's disease has been rejected for widespread use by the NHS in England ...

Regulator cited significant uncertainties about the drug’s benefits, as well as the high costs to treat its severe side ...

The most effective drug for Alzheimer’s has been blocked for use on the NHS. Regulators have declared the new treatment for ...

Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after ...